Clinical trial NCT01427400: The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
Official title: The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Keywords: Breast expander
Breast reconstruction
Implants
Botox
Lead sponsor: University of British Columbia
Sponsor class: OTHER
Collaborators: name: Vancouver Coastal Health
name: Providence Health & Services
name: Fraser Health
First posted: 2011-09-01
Enrollment: 128
Sex: FEMALE
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Breast reconstruction is a common procedure with over 86,000 breast reconstruction procedures performed in the United States in 2009. This is a 1.5-fold increase since 2007. Of these breast reconstructions, 65% use a tissue expander/implant technique. Although satisfactory results can be achieved with a single-stage technique, a two-stage approach is considered more reliable, allowing for precise positioning of the inframammary fold and an opportune time to perform a capsulotomy to increase the breast skin flap by releasing the soft tissue.

The placement of the tissue expander and implant under the chest muscles is thought to minimize the incidence of capsular contracture, expander exposure, and in addition, produce acceptable aesthetic results. However, discomfort is often associated with this submuscular placement of a tissue expander or implant, specifically during the expansion phase. Patients undergoing immediate reconstruction using submuscular implants have been shown to have higher analgesic requirements and to have higher pain scores post-operatively, compared to non-reconstructed patients. An uncomfortable reconstruction can lead to under-filling of the expander, a longer expansion process, abandonment of reconstruction, and a compromised quality of life. The use of Botulinum Toxin A (Botox) injections into the chest muscles at the time of surgery may help ease the discomfort that is often associated with this procedure.

The investigators propose a prospective double-blind randomized placebo-controlled trial of patients undergoing tissue expander/implant reconstruction. The information gathered from this analysis will provide a greater understanding of the effects of Botox in the setting of two-stage tissue expander/implant breast reconstruction, with the goal to improve patient satisfaction and quality of life.

Detailed description: Currently, there is level C evidence for the efficacy of Botox in the treatment of postoperative pain and muscle spasms in breast reconstruction patients. Additional high-level evidence is necessary to justify the use of Botox in breast cancer patients, which potentially will improve the reconstructive process for these patients and improve quality of life. Additionally, there have been no studies to date that have evaluated patient satisfaction and QOL in this setting. The investigators will evaluate patient satisfaction and QOL using the Breast-Q© during different time periods after two-stage tissue expander/implant reconstruction. Previous studies have demonstrated a reduction in pain when Botox was used during tissue expander/implant breast reconstruction, however, these studies were not blinded which may introduce bias. Additionally, a timely reconstruction is important to the patient, and a decrease in pain may result in a shorter fill interval and an increased total amount of volume in the tissue expander. The investigators will therefore document both the amount of expansion that a patient can tolerate at each follow-up visit and the total volume expanded, and compare the data between the Botox group to the group assigned to placebo.

Eligibility criteria: Inclusion Criteria:

* Patients who undergo immediate, post-mastectomy, unilateral or bilateral, tissue expander/implant reconstruction
* Patients older than 21, with no upper age limit
* English-speaking, or has an appropriate translator

Exclusion Criteria:

* Patient declines inclusion in the study
* Patients who undergo a single-stage implant reconstruction or combined autogenous tissue expander/implant reconstruction
* Previous history of radiation
* Previous breast surgery with implants
* Previous history of axillary lymph node dissection
* Patients who are pregnant
* Patients with hepatorenal failure
* Patients with known hypersensitivity to Botulinum Toxin-A
* Patients with significant mastectomy flap ischemia at time of tissue expander placement

Primary outcomes:
measure: Change from Baseline in Quality of life and patient satisfaction using the Breast-Q
timeFrame: Before 1st surgery, 2 weeks, ~6-8weeks, Before 2nd Surgery, 6 months, and 12 months post-op
Secondary outcomes:
measure: Patient-reported pain,using the BPI (Brief Pain Inventory) and Pain Diary during the expansion phase (initial to final expansion) and in the long-term period (6 and 12 months).
timeFrame: BPI (before 1st surgery, day of surgery, 2 weeks, ~ 6 - 8 weeks, before 2nd surgery, 6 months and 12 months). After 1st surgery, pain diary is to be filled out every evening at the same time.
measure: Aesthetic outcome
timeFrame: 6 months and 12 months (after 2nd surgery)
Other outcomes:
Locations:
city: Surrey
country: Canada
facility: Plastic, Reconstructive and Cosmetic Surgery
state: British Columbia
city: Vancouver
country: Canada
facility: Canada, British Columbia
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Adelyn Ho, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References: